CAP (cyclophosphamide, doxorubicin, and cisplatin) regimen in adrenal cortical carcinoma.

Abstract

Eleven patients with advanced progressive metastatic adrenal cortical carcinoma, for whom no further standard therapy was available, were entered into a phase II study of cyclophosphamide, doxorubicin, and cisplatin (CAP) combination chemotherapy. Two partial responses and six disease stabilizations were observed. Patients with partial responses survived 18+ and 23 months; the median survival of patients with disease stabilization was 10+ months. The total group had a median survival of 10+ months. These results, together with the modest toxicity, suggest that further study of the combination is warranted.

• Authors: H van Slooten, A T van Oosterom
• Journal: Cancer treatment reports (Cancer Treat Rep) Vol. 67 Issue 4 Pg. 377-9 (Apr 1983) ISSN: 0361-5960 [Print] United States
• PMID: 6687835 (Publication Type: Journal Article)

Chemical References

• Doxorubicin
• Cyclophosphamide
• Cisplatin

Topics

• Adolescent
• Adrenal Cortex Neoplasms (drug therapy)
• Adult
• Antineoplastic Combined Chemotherapy Protocols
• Cisplatin (administration & dosage)
• Cyclophosphamide (administration & dosage)
• Doxorubicin (administration & dosage)
• Drug Evaluation
• Drug Therapy, Combination
• Female
• Humans
• Male
• Middle Aged
• Neoplasm Metastasis
• Prognosis